Immunogenicity of the Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in patients with cirrhosis.

IF 1.6 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Scandinavian Journal of Gastroenterology Pub Date : 2025-06-17 DOI:10.1080/00365521.2025.2518466

Samer Al-Dury, Sigrun Einarsdottir, Ellen Fridriksson, Linn Dahlsten Andius, Hao Wang, Sinan Sharba, Amin Mountagui, Johan Waern, Johan Ringlander, Jesper Waldenström, Anna Martner, Kristoffer Hellstrand, Martin Lagging

{"title":"Immunogenicity of the Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in patients with cirrhosis.","authors":"Samer Al-Dury, Sigrun Einarsdottir, Ellen Fridriksson, Linn Dahlsten Andius, Hao Wang, Sinan Sharba, Amin Mountagui, Johan Waern, Johan Ringlander, Jesper Waldenström, Anna Martner, Kristoffer Hellstrand, Martin Lagging","doi":"10.1080/00365521.2025.2518466","DOIUrl":null,"url":null,"abstract":"Objective: : To evaluate the durability of immune responses following prior COVID-19 vaccinations and assess the immunogenicity of a fifth mRNA-based COVID-19 booster dose in patients with liver cirrhosis.Materials and Methods: In this longitudinal cohort study, 33 patients with liver cirrhosis received a fifth booster dose of the Comirnaty Omicron XBB.1.5® (Pfizer-BioNTech) mRNA vaccine. Peripheral blood samples were collected prior to and four weeks after vaccination. Humoral immunity was assessed by measuring serum antibodies against the receptor-binding domain of spike (anti-RBD-S1) and nucleocapsid proteins. Cellular immunity was evaluated by quantifying ex vivo Spike 1 (S1)-specific T-cell responses, specifically IL-2 release.Results: The fifth mRNA vaccine dose led to a significant increase in anti-RBD-S1 antibody levels and S1-induced IL-2 release, indicating enhanced humoral and cellular immune responses. The optimal interval for booster administration to maintain elevated antibody titers was identified as 10-12 months. Additionally, a history of prior COVID-19 infection significantly influenced post-booster antibody responses.Conclusions: A fifth mRNA-based COVID-19 booster dose significantly augments both humoral and cellular immunity in patients with liver cirrhosis. These findings support the use of a single annual booster dose to maintain adequate immune protection in this vulnerable population.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-9"},"PeriodicalIF":1.6000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00365521.2025.2518466","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: : To evaluate the durability of immune responses following prior COVID-19 vaccinations and assess the immunogenicity of a fifth mRNA-based COVID-19 booster dose in patients with liver cirrhosis.

Materials and Methods: In this longitudinal cohort study, 33 patients with liver cirrhosis received a fifth booster dose of the Comirnaty Omicron XBB.1.5® (Pfizer-BioNTech) mRNA vaccine. Peripheral blood samples were collected prior to and four weeks after vaccination. Humoral immunity was assessed by measuring serum antibodies against the receptor-binding domain of spike (anti-RBD-S1) and nucleocapsid proteins. Cellular immunity was evaluated by quantifying ex vivo Spike 1 (S1)-specific T-cell responses, specifically IL-2 release.

Results: The fifth mRNA vaccine dose led to a significant increase in anti-RBD-S1 antibody levels and S1-induced IL-2 release, indicating enhanced humoral and cellular immune responses. The optimal interval for booster administration to maintain elevated antibody titers was identified as 10-12 months. Additionally, a history of prior COVID-19 infection significantly influenced post-booster antibody responses.

Conclusions: A fifth mRNA-based COVID-19 booster dose significantly augments both humoral and cellular immunity in patients with liver cirrhosis. These findings support the use of a single annual booster dose to maintain adequate immune protection in this vulnerable population.

查看原文本刊更多论文

Comirnaty Omicron XBB.1.5增强COVID-19 mRNA疫苗在肝硬化患者中的免疫原性

目的：评估先前接种COVID-19疫苗后免疫反应的持久性，并评估肝硬化患者第五剂基于mrna的COVID-19增强剂的免疫原性。材料和方法：在这项纵向队列研究中，33名肝硬化患者接受了第五剂Comirnaty Omicron XBB.1.5®（Pfizer-BioNTech） mRNA疫苗的加强剂。接种前和接种后四周采集外周血样本。体液免疫通过测定针对刺突受体结合域（抗rbd - s1）和核衣壳蛋白的血清抗体来评估。通过定量体外Spike 1 （S1）特异性t细胞反应，特别是IL-2释放来评估细胞免疫。结果：第5次mRNA疫苗剂量导致抗rbd - s1抗体水平和s1诱导的IL-2释放显著增加，表明体液和细胞免疫反应增强。加强给药以维持抗体滴度升高的最佳间隔确定为10-12个月。此外，既往COVID-19感染史显著影响增强后抗体反应。结论：第五剂基于mrna的COVID-19增强剂可显著增强肝硬化患者的体液和细胞免疫。这些发现支持使用每年一次的加强剂量来维持这一脆弱人群的充分免疫保护。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Scandinavian Journal of Gastroenterology 医学-胃肠肝病学

CiteScore

3.40

自引率

5.30%

发文量

222

审稿时长

3-8 weeks

期刊介绍： The Scandinavian Journal of Gastroenterology is one of the most important journals for international medical research in gastroenterology and hepatology with international contributors, Editorial Board, and distribution